# Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

> **NCT05518994** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Henan Provincial People's Hospital** · enrollment: 70 (estimated)

## Conditions studied

- Astrocytoma of Brain

## Interventions

- **DRUG:** Tislelizumab plus Bevacizumab

## Key facts

- **NCT ID:** NCT05518994
- **Lead sponsor:** Henan Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-12-01
- **Primary completion:** 2025-12
- **Final completion:** 2027-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05518994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05518994, "Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT05518994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*